Canada Markets close in 1 hr 47 mins

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.87+3.95 (+135.27%)
As of 04:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.92
Open3.72
Bid6.74 x 1000
Ask7.00 x 900
Day's Range3.69 - 8.90
52 Week Range2.84 - 45.00
Volume266,840,977
Avg. Volume10,701,290
Market Cap130.417M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Motley Fool

    Why Longeveron Stock Is Skyrocketing Today

    Shares of Longeveron (NASDAQ: LGVN) were skyrocketing 72.9% as of 11:51 a.m. ET on Wednesday after more than doubling earlier in the day. An epic short squeeze appears to be underway. Longeveron announced on Nov. 18 that the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease designation to experimental drug Lomecel-B in treating a rare congenital heart defect.

  • Bloomberg

    Retail Traders Jump Back Into Tiny Biotechs Ahead of Holiday

    (Bloomberg) -- Two tiny biotechs, ISpecimen Inc. and Longeveron Inc., are the latest to see their stocks caught up in a social media-fueled frenzy ahead of a U.S. trading holiday. Most Read from BloombergAsia’s Richest Man Looks to Walton Family Playbook on SuccessionBillionaire Family Feud Puts a Century-Old Business Empire in JeopardyThe 24-Year-Old Aiming to Dethrone Victoria’s SecretThe Winners and Losers From a Year of Ranking Covid ResilienceNew York City Is Building a Wall of Oysters to F

  • GlobeNewswire

    U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

    Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per yearMIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of